NasdaqGS:AMGNBiotechs
Positive Phase 3 Data for Rocatinlimab Might Change the Case for Investing in Amgen (AMGN)
In early September 2025, Amgen and Kyowa Kirin announced preliminary top-line results from the Phase 3 ASCEND study, showing their investigational therapy rocatinlimab provided sustained efficacy and a favorable safety profile in adults and adolescents with moderate to severe atopic dermatitis.
This data suggests rocatinlimab’s differentiated mechanism may allow for less frequent maintenance dosing, potentially setting it apart in the atopic dermatitis treatment landscape compared to...